Comparison
PT-141 vs Testosterone
Side-by-side of PT-141 and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | PT-141 | Testosterone |
|---|---|---|
| Category | peptide | hormone |
| Also known as | Bremelanotide, Vyleesi | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 2.7 | 192 |
| Typical dose (mg) ↗ | 1.75 | 150 |
| Dosing frequency | as needed (max once per 24 hours, max 8 per month) | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | subcutaneous | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 0.75 | 24 |
| Peak (hr) | 1.5 | 72 |
| Molecular weight | 1025.18 | 288.42 |
| Molecular formula | C50H68N14O10 | C19H28O2 |
| Mechanism | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. | Schedule III controlled substance (US); WADA banned |
| WADA status | allowed | banned |
| DEA / Rx | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation | Schedule III |
| Pregnancy | Not recommended; contraindicated during pregnancy per Vyleesi label | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 189691-06-3 | 58-22-0 |
| PubChem CID | 9941379 | 6013 |
| Wikidata | Q422059 | Q150726 |
Safety profile
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Testosterone comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is libido, pick PT-141.
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is body composition, pick Testosterone.
Edge case: If you cannot self-administer injections, Testosterone is the only oral option in this pair.
Default choice: Testosterone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between PT-141 and Testosterone?
PT-141 and Testosterone differ in category (peptide vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, PT-141 or Testosterone?
PT-141 half-life is 2.7 hours; Testosterone half-life is 192 hours.
Can you stack PT-141 with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper